These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z; Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562 [TBL] [Abstract][Full Text] [Related]
6. Biofeedback training for detrusor overactivity in children. Yamanishi T; Yasuda K; Murayama N; Sakakibara R; Uchiyama T; Ito H J Urol; 2000 Nov; 164(5):1686-90. PubMed ID: 11025748 [TBL] [Abstract][Full Text] [Related]
7. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Kuo HC Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967 [TBL] [Abstract][Full Text] [Related]
8. Bladder contraction strength parameters poorly predict the necessity of long-term catheterization after a pubovaginal rectus fascial sling procedure. Groen J; Bosch JL J Urol; 2004 Sep; 172(3):1006-9. PubMed ID: 15311024 [TBL] [Abstract][Full Text] [Related]
9. Refractory monosymptomatic nocturnal enuresis: a combined stepwise approach in childhood and follow-up into adolescence, with attention to the clinical value of normalizing bladder capacity. Vermandel A; de Wachter S; Wyndaele JJ BJU Int; 2005 Sep; 96(4):629-33. PubMed ID: 16104923 [TBL] [Abstract][Full Text] [Related]
10. Functional bladder capacity after bladder biofeedback predicts long-term outcome in children with nocturnal enuresis. Hoekx L; Vermandel A; Wyndaele JJ Scand J Urol Nephrol; 2003; 37(2):120-3. PubMed ID: 12745719 [TBL] [Abstract][Full Text] [Related]
11. The effect of biofeedback treatment on voiding and urodynamic parameters in children with voiding dysfunction. Yagci S; Kibar Y; Akay O; Kilic S; Erdemir F; Gok F; Dayanc M J Urol; 2005 Nov; 174(5):1994-7; discussion 1997-8. PubMed ID: 16217376 [TBL] [Abstract][Full Text] [Related]
12. Localized contractions in the normal human bladder and in urinary urgency. Drake MJ; Harvey IJ; Gillespie JI; Van Duyl WA BJU Int; 2005 May; 95(7):1002-5. PubMed ID: 15839921 [TBL] [Abstract][Full Text] [Related]
13. Lower urinary tract symptoms in young men: videourodynamic findings and correlation with noninvasive measures. Nitti VW; Lefkowitz G; Ficazzola M; Dixon CM J Urol; 2002 Jul; 168(1):135-8. PubMed ID: 12050507 [TBL] [Abstract][Full Text] [Related]
14. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
15. Detrusor contraction duration as a urodynamic parameter of bladder outlet obstruction for evaluating men with lower urinary tract symptoms. Ameda K; Steele GS; Sullivan MP; Stember D; Yalla SV J Urol; 1998 Aug; 160(2):482-6. PubMed ID: 9679903 [TBL] [Abstract][Full Text] [Related]
16. [New urodynamic data of sensory urgency in women]. Virseda Chamorro M; Salinas Casado J; Vazquez Alba D; Martín Garcia C Arch Esp Urol; 2003 Sep; 56(7):785-91. PubMed ID: 14595882 [TBL] [Abstract][Full Text] [Related]
17. Comparison of fesoterodine and tolterodine in patients with overactive bladder. Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298 [TBL] [Abstract][Full Text] [Related]
18. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Apostolidis A; Gonzales GE; Fowler CJ Eur Urol; 2006 Dec; 50(6):1299-305. PubMed ID: 16697519 [TBL] [Abstract][Full Text] [Related]